|
melanoma
|
0.310 |
PosttranslationalModification
|
disease |
BEFREE |
Furthermore, we show that promoter hypermethylation accounts for the silencing of the WFDC1 gene in 20% of the melanoma cell lines examined.
|
19488830 |
2009 |
|
melanoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
Epigenetic silencing of novel tumor suppressors in malignant melanoma.
|
17145863 |
2006 |
|
Malignant neoplasm of breast
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Co-regulatory networks of human serum proteins link genetics to disease.
|
30072576 |
2018 |
|
Alcohol consumption
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Gene-alcohol interactions identify several novel blood pressure loci including a promising locus near SLC16A9.
|
24376456 |
2013 |
|
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Gene-alcohol interactions identify several novel blood pressure loci including a promising locus near SLC16A9.
|
24376456 |
2013 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
WFDC1/ps20 expression is frequently downregulated or lost in prostate cancer (PCa) and ps20 has demonstrated growth-suppressive functions in numerous tumour model systems, although the mechanisms of this phenomenon are not understood.
|
27115470 |
2016 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Gene expression microarray analysis and further expression validation suggests that the Dickkopf-1 (Dkk1) gene is up-regulated in WFDC1 over-expressing cell lines, suggesting that the tumor suppressive function of WFDC1 may be partially a result of up-regulated Dkk1 gene expression, which is known to be a potent inhibitor of the Wnt signaling pathway.
|
19488830 |
2009 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Taken together, our data suggest an important role for WFDC1 in inhibiting proliferation of both tumors and senescent cells.
|
18842679 |
2009 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We, therefore, propose that WFDC1/ps20 may not be a classical tumor suppressor gene, but might play a role in the maintenance of the normal extra cellular matrix milieu in the prostate.
|
15305342 |
2004 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
To address the potential effects of ps20 in a tumor microenvironment, we used the DRS model to evaluate both angiogenesis and tumorigenesis of tumors generated under either ps20 or control conditions.
|
14522910 |
2003 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We further investigated the role of WFDC1 as a tumour suppressor gene candidate in five hepatocellular cell lines and in tumours exhibiting LOH by means of mutation, promoter methylation and gene expression analysis.
|
12032731 |
2002 |
|
Malignant neoplasm of prostate
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The WFDC1 gene is frequently down-regulated or lost in prostate cancer, and the encoded protein, ps20, has been implicated in epithelial cell behaviour and angiogenesis.
|
30423385 |
2019 |
|
Prostate carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The WFDC1 gene is frequently down-regulated or lost in prostate cancer, and the encoded protein, ps20, has been implicated in epithelial cell behaviour and angiogenesis.
|
30423385 |
2019 |
|
Malignant neoplasm of prostate
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
WPMY-1 stromal cells expressing ps20 were characterised by transcriptome microarray and the function of WPMY-1 conditioned media on growth of PCa cell lines was assessed.
|
27115470 |
2016 |
|
Prostate carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
WPMY-1 stromal cells expressing ps20 were characterised by transcriptome microarray and the function of WPMY-1 conditioned media on growth of PCa cell lines was assessed.
|
27115470 |
2016 |
|
Malignant neoplasm of prostate
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
We, therefore, chose to examine WFDC1/ps20 for mutations and expression changes in prostate cancer.
|
15305342 |
2004 |
|
Prostate carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
We, therefore, chose to examine WFDC1/ps20 for mutations and expression changes in prostate cancer.
|
15305342 |
2004 |
|
Malignant neoplasm of prostate
|
0.040 |
Biomarker
|
disease |
BEFREE |
Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model.
|
14522910 |
2003 |
|
Prostate carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model.
|
14522910 |
2003 |
|
Carcinogenesis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Modulated expression of WFDC1 during carcinogenesis and cellular senescence.
|
18842679 |
2009 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
To address the potential effects of ps20 in a tumor microenvironment, we used the DRS model to evaluate both angiogenesis and tumorigenesis of tumors generated under either ps20 or control conditions.
|
14522910 |
2003 |
|
Carcinogenesis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Identification and characterization of the WFDC1 gene may aid in better understanding the potential role of this gene and ps20 in prostate biology and carcinogenesis.
|
10967136 |
2000 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Enhanced expression of either WFDC1 or IL-17D potently represses SORBS2 depletion-mediated cancer metastasis promotion.
|
29548303 |
2018 |
|
Malignant Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
The WFDC1 gene was mapped by FISH analysis to human Chromosome (Chr) 16q24, an area of frequent loss of heterozygosity (LOH) previously identified in multiple cancers including prostate, breast, hepatocellular, and Wilms' tumor.
|
10967136 |
2000 |